Incorporated in 1984, Aarti Drugs Limited manufactures specialty chemicals and bulk drugs.
The company manufactures over 40 products comprising bulk actives, key intermediates, and specialty chemicals. Its product portfolio includes anti-biotic, anti-protozoal, anti-inflammatory, anti-fungal, anti-diabetic, cardio-protectant, vitamins, anti-arthritis, and sedative therapeutic groups that help in lifesaving and lifestyle-related diseases.
Aarti Drugs has nine manufacturing units located at Tarapur (Maharashtra) and two manufacturing units located at Sarigam (Gujarat), most of them being GMP certified. The company exports its products to over 100 countries worldwide. The Company has also got approvals from various authorities such as WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS.
The company recorded a total revenue of ₹2,71,824.75 lakhs, ₹2,49,996.17 lakhs, and ₹2,15,930.50 lakhs in 2023, 2022, and 2021 respectively.
Aa
Aarti Drugs Buyback 2023 Detail
| Issue Period | August 9, 2023 – August 17, 2023 |
| Security Name | Aarti Drugs Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 665,000.00 |
| Issue Size (Amount) | ₹59.85 Crores |
| Buyback Price | ₹900 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
Aarti Drugs Buyback 2023 Issue Timetable
| Last Date to buy shares | August 3, 2023 |
| Record Date | August 4, 2023 |
| Offer Opens On | August 9, 2023 |
| Last Date for receipt of Tender Forms | August 17, 2023 |
| Offer Closes On * | August 17, 2023 |
| Finalisation of Buyback Acceptance | August 23, 2023 |
| Last Date for settlment of bids | August 24, 2023 |
| Last Date for Extinguishment of Shares | September 4, 2023 |
* Last Date to Tender shares on Zerodha : August 16, 2023
Buyback Ratio
| Category | Entitlement Ratio of Buyback | Shares Offered |
|---|---|---|
| Reserved Category for Small Shareholders | 2 Equity Shares out of every 157 Fully paid-up Equity Shares held on the Record Date. | 99,750.00 |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 150 Fully paid-up Equity Shares held on the Record Date. | 565,250.00 |
Company Financials
| Period Ended | 31 Mar 2019 | 31 Mar 2020 | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 1,455.49 | 1,576.50 | 1,766.01 | 2,207.96 | 2,421.40 |
| Revenue | 1,436.09 | 1,626.75 | 2,159.31 | 2,499.96 | 2,718.25 |
| Profit After Tax | 89.75 | 141.40 | 280.40 | 205.00 | 166.36 |
| Net Worth | 904.27 | 1,026.52 | 1,184.10 | ||
| Reserves and Surplus | |||||
| Total Borrowing |
Amount in ₹ Crore
Stock price at BSE (in preceding 3 months)
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jun-2023 | 492.95 | 437.35 | 460.04 |
| May-2023 | 478.25 | 423.00 | 452.48 |
| Apr-2023 | 436.00 | 336.05 | 407.57 |
Stock price at NSE (in preceding 3 months)
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jun-2023 | 493.00 | 439.10 | 459.93 |
| May-2023 | 478.00 | 422.85 | 452.23 |
| Apr-2023 | 436.00 | 336.00 | 407.91 |
Necessity of the Issue
The Buy Back is being proposed by the Company to fulfill the following objectives:
- The Buyback will help the company to return surplus cash to its shareholders holding Equity Shares.
- The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by a reduction in the equity base, thereby leading to a long-term increase in shareholders value.
- The Buyback gives an option to the shareholders holding Equity Shares of the company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment.
- The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would get classified as Small Shareholders.
Company Contact Information
Aarti Drugs Limited
Plot No. – N-198,
MIDC, Tarapur,
Tal – Palghar, Dist. Palghar – 401506
Phone: +91 22 2401 9025
Email: admin@aartidrugs.com
Website: https://www.aartidrugs.co.in/